Nyxoah Appoints Scott Holstine as Chief Commercial Officer
July 15 2024 - 1:00AM
Nyxoah Appoints Scott Holstine as Chief
Commercial Officer
Mont-Saint-Guibert, Belgium – July 15,
2024, 8:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq:
NYXH) (“Nyxoah” or the “Company”), a medical technology
company focused on the development and commercialization of
innovative solutions to treat Obstructive Sleep Apnea (OSA), today
announced the appointment of Scott Holstine as Chief Commercial
Officer. In this role, Scott will lead the commercial operations of
Nyxoah enabling a successful U.S. launch.
Scott brings over 26 years of experience in the
medical device industry with a proven track record in U.S. product
launches, building and leading commercial organizations trademarked
by strong operational execution. Scott is a passionate advocate for
people and talent development. Scott graduated with the
Superintendent’s Award for Excellence (Star Wreath) from the United
States Military Academy at West Point, NY. After serving as a
Captain in the U.S. Army, Scott received his MBA from the
University of Minnesota, Carlson School of Management –
Minneapolis, MN.
“As we expect FDA approval by the end of 2024,
the hiring of an experienced commercial leader is instrumental in
further accelerating our U.S. go-to-market strategy into a concrete
launch execution plan. This starts with having a commercial team
fully operational by year-end. Scott is a dynamic and creative
leader with countless accomplishments in building high-performing
teams and developing new markets for innovative technologies,”
commented Olivier Taelman, Nyxoah Chief Executive Officer. “This
appointment is the kickoff of building a team of world-class
patient- and clinician-focused professionals, supporting Nyxoah’s
mission to make sleep simple again for OSA patients.”
“This is a promising time for patients with OSA.
Nyxoah’s strong DREAM study results and Genio’s success in markets
outside of the U.S. have demonstrated the potential of Genio’s
breakthrough and unique solution. Both patients and physicians are
eagerly awaiting a second player in the HGNS field. I am thrilled
to be part of the team building out a patient-focused commercial
operation that prioritizes the success of our healthcare provider
partners in treating OSA,” added Scott.
About NyxoahNyxoah is a medical
technology company focused on the development and commercialization
of innovative solutions to treat Obstructive Sleep Apnea (OSA).
Nyxoah’s lead solution is the Genio® system, a patient-centered,
leadless and battery-free hypoglossal neurostimulation therapy for
OSA, the world’s most common sleep disordered breathing condition
that is associated with increased mortality risk and cardiovascular
comorbidities. Nyxoah is driven by the vision that OSA patients
should enjoy restful nights and feel enabled to live their life to
its fullest.
Following the successful completion of the BLAST
OSA study, the Genio® system received its European CE Mark in 2019.
Nyxoah completed two successful IPOs: on Euronext Brussels in
September 2020 and NASDAQ in July 2021. Following the positive
outcomes of the BETTER SLEEP study, Nyxoah received CE mark
approval for the expansion of its therapeutic indications to
Complete Concentric Collapse (CCC) patients, currently
contraindicated in competitors’ therapy. Additionally, the Company
announced positive outcomes from the DREAM IDE pivotal study for
FDA and U.S. commercialization approval.
For more information, please see the Company’s
annual report for the financial year 2023 and visit
http://www.nyxoah.com/.
Caution – CE marked since 2019.
Investigational device in the United States. Limited by U.S.
federal law to investigational use in the United States.
Forward-looking statements
Certain statements, beliefs and opinions in this
press release are forward-looking, which reflect the Company’s or,
as appropriate, the Company directors’ or managements’ current
expectations regarding the entry into of the loan facility
agreement and the synthetic warrant agreement with the EIB; the use
of proceeds from the loan facility agreement; the Genio® system and
ongoing clinical studies of the Genio® system; the potential
advantages of the Genio® system; Nyxoah’s goals with respect to the
development, regulatory pathway and potential use of the Genio®
system; the utility of clinical data in potentially obtaining FDA
approval of the Genio® system; reporting data from Nyxoah’s DREAM
U.S. pivotal trial; filing for FDA approval; and entrance to the
U.S. market. By their nature, forward-looking statements involve a
number of risks, uncertainties, assumptions and other factors that
could cause actual results or events to differ materially from
those expressed or implied by the forward-looking statements. These
risks, uncertainties, assumptions and factors could adversely
affect the outcome and financial effects of the plans and events
described herein. Additionally, these risks and uncertainties
include, but are not limited to, the risks and uncertainties set
forth in the “Risk Factors” section of the Company’s Annual Report
on Form 20-F for the year ended December 31, 2023, filed with the
Securities and Exchange Commission (“SEC”) on March 20, 2024, and
subsequent reports that the Company files with the SEC. A multitude
of factors including, but not limited to, changes in demand,
competition and technology, can cause actual events, performance or
results to differ significantly from any anticipated development.
Forward looking statements contained in this press release
regarding past trends or activities are not guarantees of future
performance and should not be taken as a representation that such
trends or activities will continue in the future. In addition, even
if actual results or developments are consistent with the
forward-looking statements contained in this press release, those
results or developments may not be indicative of results or
developments in future periods. No representations and warranties
are made as to the accuracy or fairness of such forward-looking
statements. As a result, the Company expressly disclaims any
obligation or undertaking to release any updates or revisions to
any forward-looking statements in this press release as a result of
any change in expectations or any change in events, conditions,
assumptions or circumstances on which these forward-looking
statements are based, except if specifically required to do so by
law or regulation. Neither the Company nor its advisers or
representatives nor any of its subsidiary undertakings or any such
person's officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from errors nor
does either accept any responsibility for the future accuracy of
the forward-looking statements contained in this press release or
the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak
only as of the date of this press release.
Contact:
NyxoahDavid DeMartino, Chief
Strategy OfficerIR@nyxoah.com
For
MediaBelgium/FranceBackstage Communication – Gunther De
Backergunther@backstagecom.be
International/GermanyMC Services – Anne
Henneckeanne.hennecke@mc-services.eu
- ENGLISH_Nyxoah Appoints Scott Holstine as Chief Commercial
Officer_FINAL
Nyxoah (EU:NYXH)
Historical Stock Chart
From Oct 2024 to Nov 2024
Nyxoah (EU:NYXH)
Historical Stock Chart
From Nov 2023 to Nov 2024
